Welcome to our dedicated page for Entrada Therapeutics SEC filings (Ticker: TRDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Entrada Therapeutics, Inc. (Nasdaq: TRDA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Entrada is a clinical-stage biopharmaceutical company developing RNA- and protein-based therapeutics using its Endosomal Escape Vehicle (EEV™) technology for neuromuscular, ocular and other diseases.
For TRDA, key filings include periodic reports and current reports on Form 8-K. Recent Form 8-K filings furnished by Entrada cover quarterly financial results and corporate updates, such as results for the quarters ended June 30, 2025 and September 30, 2025. These filings confirm that Entrada’s common stock is registered on The Nasdaq Global Market under the symbol TRDA and identify the company as an emerging growth company.
Through this page, users can review how Entrada reports on its financial condition, collaboration revenue, research and development expenses, and other operating metrics in documents that are incorporated by reference into its SEC record. While the detailed content of annual reports on Form 10-K, quarterly reports on Form 10-Q and proxy statements is not reproduced here, this filings hub is the starting point for locating those documents on EDGAR.
Stock Titan enhances access to Entrada’s SEC filings by organizing them chronologically and highlighting document types that matter to investors, such as Forms 8-K, 10-K, 10-Q and, when applicable, insider transaction reports on Form 4. AI-driven tools can help summarize lengthy filings and clarify technical language, allowing readers to more quickly understand how Entrada describes its EEV platform, clinical programs and financial results in its official regulatory disclosures.
Entrada Therapeutics (TRDA) filed its Q3 2025 10‑Q, reporting a sharp year-over-year step-down in collaboration revenue and a return to losses as prior-period milestone revenue tapered. Collaboration revenue was $1.6 million for the quarter versus $19.6 million a year ago, and $24.1 million for the nine months versus $173.4 million in 2024. Research and development expenses rose to $38.4 million in Q3 (from $31.3 million), reflecting advancing DMD programs; general and administrative expenses were $10.3 million (from $10.0 million).
The company posted a net loss of $44.1 million for Q3 (vs. $14.0 million loss) and a net loss of $104.6 million year‑to‑date (vs. $64.5 million income), with Q3 EPS of $(1.06). Cash, cash equivalents and marketable securities totaled $326.8 million as of September 30, 2025, which management states is sufficient to fund operations into the third quarter of 2027. Operating cash use was $96.3 million year‑to‑date. Deferred revenue declined to $0.5 million, consistent with revenue recognition on the Vertex collaboration.
Pipeline updates include ongoing Phase 1/2 studies for ENTR‑601‑44 and ENTR‑601‑45 in DMD, UK filing for ENTR‑601‑50, and a planned ENTR‑601‑51 filing in 2026. A 20% workforce reduction in April 2025 resulted in a $1.9 million charge. Shares outstanding were 38,219,232 as of October 31, 2025.
Entrada Therapeutics, Inc. filed a current report describing that it announced financial results for the quarter ended September 30, 2025, along with other corporate updates. These results and updates are provided in a press release dated November 6, 2025, which is included as an exhibit to the report.
The press release is furnished, not filed, meaning it is not automatically subject to certain Exchange Act liabilities or incorporated into other securities law filings unless specifically referenced.
Dipal Doshi, who serves as CEO and a director of Entrada Therapeutics, Inc. (TRDA), reported a sale of 8,723 shares of common stock on 09/02/2025 to cover tax withholding obligations arising from vested restricted stock units. The sale price shown is a weighted average of $5.4302 with reported trade prices ranging from $5.36 to $5.58. After this transaction, the reporting person beneficially owned 415,664 shares directly. The Form 4 was filed by one reporting person and signed by an attorney-in-fact on 09/04/2025.
Entrada Therapeutics insider sale to cover RSU taxes The filing shows Nathan J. Dowden, President & COO of Entrada Therapeutics (TRDA), reported a sale of 1,746 shares of common stock on 09/02/2025 at a weighted average price of $5.4302. After the sale he beneficially owned 179,059 shares. The filing states the sale was to satisfy tax withholding obligations arising from vested restricted stock units and was executed in multiple transactions at prices ranging $5.36 to $5.58.
Sethuraman Natarajan, an officer at Entrada Therapeutics, Inc. (TRDA), reported a sale of 1,760 shares of the company's common stock on 09/02/2025 to satisfy tax withholding obligations from vested restricted stock units. The filing shows a weighted-average sale price of $5.4302, with individual trade prices ranging from $5.36 to $5.58. After the reported disposition, the reporting person beneficially owns 197,899 shares. The Form 4 was signed by an attorney-in-fact on 09/04/2025. The filing is a routine insider report documenting a tax-withholding sale tied to RSU vesting and does not state any other transactions or derivative holdings.
Entrada Therapeutics CFO Kory James sold 1,734 shares on 09/02/2025 to cover tax withholding arising from RSU vesting. The weighted-average price for the sales was $5.4302, with transaction prices reported between $5.36 and $5.58. After the sale, the reporting person beneficially owned 118,936 shares, held directly. The Form 4 was filed indicating the sale was to satisfy withholding obligations tied to previously granted restricted stock units.
Janus Henderson Group plc reports beneficial ownership of 1,521,281 shares of Entrada Therapeutics common stock, representing 4.0% of the class. The filing states Janus Henderson has no sole voting or dispositive power and shared voting and dispositive power over all reported shares.
The filing identifies certain indirect subsidiaries (including JHIUS, JHIUKL and JHIAIFML) as registered investment advisers furnishing advice to Managed Portfolios and includes a certification that the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Entrada Therapeutics, Inc. (Form 10-Q) — quarter ended June 30, 2025. The company reported $72.5M cash and cash equivalents and $281.5M marketable securities (total $354.0M) and total assets of $448.8M as of June 30, 2025. Total liabilities were $69.3M and accumulated deficit was $189.8M. Shares outstanding: 38,033,970 as of June 30, 2025 (38,037,079 as of July 31, 2025).
Operational and financial results: collaboration revenue was $1.95M for Q2 2025 and $22.51M for the six months ended June 30, 2025 (versus $94.69M and $153.81M in the comparable 2024 periods). R&D expense was $37.88M in Q2 2025 and $69.95M for six months; G&A expense was $10.92M and $21.20M, respectively. Net loss: $43.10M for the quarter and $60.45M for six months (basic net loss per share Q2: $1.04; six months: $1.47).
Corporate developments: first patient dosed in ELEVATE-44-201 and ELEVATE-45-201 initiated; company expects to file for ENTR-601-50 in Q4 2025. Vertex collaboration revenue recognition included a cumulative catch-up adjustment of $12.3M during H1 2025 and the remaining transaction price allocated to unsatisfied obligations was $0.9M at June 30, 2025. The company implemented a ~20% workforce reduction in April 2025 with a related charge of $1.9M. Management states liquidity is sufficient to fund operations into the second quarter of 2027.